MENLO PARK, Calif.–(BUSINESS WIRE)–Phathom Pharmaceuticals, a biopharmaceutical company focused on the
development and commercialization of novel treatments for
gastrointestinal (GI) diseases and disorders, today announced that David
Socks, Chief Executive Officer, will present at the Jefferies 2019
Healthcare Conference on Thursday, June 6, 2019 at 2:00 p.m. ET in New
York, NY.
About Phathom Pharmaceuticals
Phathom Pharmaceuticals is a biopharmaceutical company focused on the
development and commercialization of novel treatments for
gastrointestinal diseases and disorders. Phathom has licensed the
exclusive rights in the United States, Europe, and Canada to vonoprazan,
a novel potassium competitive acid blocker (P-CAB) in late stage
development for the treatment of acid-related disorders. In May 2019,
the company completed a $50 million term loan facility from Silicon
Valley Bank and a $90 million private financing from investors including
Frazier Healthcare Partners, Medicxi, RA Capital Management, Abingworth,
certain accounts managed by Janus Henderson Investors, BVF Partners LP,
Greenspring Associates, Richard King Mellon Foundation, Sahsen Ventures
and additional undisclosed institutional investors. For more information
about Phathom, visit the company’s website at www.phathompharma.com.
Contacts
David Socks
[email protected]
+1-650-325-5156
Liz Park
[email protected]
+1-650-319-1831
